Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

This is a Study That Aims to Estimate the Effect of Maternal Body Mass Index on the Prophylactic Dose of Norepinephrine Infusion for Preventing Hypotension in Parturient After Spinal Anesthesia

11. července 2026 aktualizováno: Ain Shams University

Effect of Maternal Body Mass Index on the Prophylactic Dose of Norepinephrine Infusion for Preventing Hypotension in Parturient After Spinal Anesthesia

This is a randomized, double-blinded controlled study that aims to estimate the effect of maternal body mass index on the prophylactic dose of norepinephrine infusion for preventing hypotension in parturient after spinal anesthesia.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

This is a randomized, double-blinded controlled study that aims to estimate the effect of maternal body mass index on the prophylactic dose of norepinephrine infusion for preventing hypotension in parturient after spinal anesthesia.

Routine preoperative investigations will be done to all patients including laboratory investigations as (complete blood picture, prothrombin time and partial thromboplastin time), age and BMI will be recorded.

All the patients will be fasting for solid food for 6-8 hours and for clear fluids for 4 hours before surgery.

Upon entry into the operating theater, all patients will be placed under standard American Society of Anesthesiologist (ASA) monitoring including 5-lead electrocardiography, pulse oximetry and non-invasive blood pressure. Baseline values of systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR) and mean blood pressure (MBP) will be measured in supine position with left uterine displacement (15 degree wedge under the right buttock) and recorded as the arithmetic mean of three consecutive measurements at least 2 min intervals with a difference of less than 10%.

As per standard practice, SBP, DBP, MBP, HR and pulse oximetry measurements will be recorded in every 2 min throughout the surgery. An 18-gauge cannula will be inserted into a large vein, The patients will receive no premedication. The study period will be the interval between the initiation of spinal injection and delivery of the fetus .

Subarachnoid block will be performed through L3-4 or L4-5 intervertebral space in the sitting position. A solution of 12.5 mg 0.5% hyperbaric bupivacaine plus 25 mic fentanyl will be injected into subarachnoid space using a 25-gauge pencil point spinal needle. After completion of subarachnoid injection, patients will be immediately placed supine on the operating table with left uterine displacement using a 15° wedge .

The highest level of sensory blockade will be assessed using a sterile needle, surgery will be permitted after a bilateral T6 sensory block .

To assure blinding, the study group will be known only to the research assistant, who would be responsible for each step of the NE administration including starting dose of NE infusion, applying a bolus dose or cessation of the infusion of NE according to the study protocol .

Immediately after the injection of the spinal anesthetic, patients will have a norepinephrine protocol corresponding to the randomized group. The study drug will be started intravenously at a rate of 50 ml/h, Lactated Ringer's solution warmed at 37°C will also administered, starting with a loading dose of 10 ml/kg given rapidly over 15 minutes and will then be adjusted to a slow maintenance flow rate to keep the vein open .

After delivery, an intravenous infusion of oxytocin (20 IU) will be slowly administered. After the end of surgery, the mother will be transported to the recovery room with routine monitoring .

NE infusion will be stopped 5 min after delivery in all patients . The intraoperative period will be divided into 2 consecutive periods . The first period is called the post-spinal period and will include the period between the completion of subarachnoid block and the time of delivery.

The subsequent period between the time of delivery and the end of the surgery will be called the post-delivery period.

All complications will be entitled according to the period in which they occurred. Accordingly, post spinal hypotension (PSH) and post delivery hypotension (PDH) will be defined as a reduction in SBP of 20% or more of the baseline value before and after the delivery, respectively .

Similarly, post-spinal severe hypotension (PSSH) and post-delivery severe hypotension (PDSH) will be defined as a decrease in SBP of 40% or more from the baseline value before and after the delivery respectively.

Management of complications: .

  1. If PSH or PDH was developed, a bolus of 10 mg ephedrine will be administered.
  2. If hypotension persisted after 2 min, a repeated dose of 10 mg ephedrine i.v. will be administered again.
  3. If PSSH or PDSH occurred, 15 mg ephedrine i.v. bolus will administered.
  4. In case of bradycardia (heart rate less than 60 beats per min ) without maternal hypotension, NE infusion will be stopped.
  5. If bradycardia persists for 2 min despite discontinuation of NE infusion, 0.5 mg of atropine i.v. bolus will be administered.
  6. Moreover, if the heart rate falls below 50 beats per min , 0.5 mg atropine i.v. bolus will be administered without waiting for 2 min. As soon as the HR increases above 60 beats per min, NE infusion will be started again at the same infusion dose corresponding to the NE group that the patient is randomized.
  7. If bradycardia is accompanied by hypotension, 10 mg ephedrine i.v. bolus will be administered.
  8. In contrast to hypotension, if the SBP is found to be 20% above the basal value, the NE infusion will be stopped and recorded as a hypertensive episode. If the systolic blood pressure falls below this determined hypertensive value, NE will be restarted at the same dose.
  9. Incidence of maternal complication as nausea and vomiting will be recorded and treated with granitryl (1 mg IV) Apgar score after delivery. Apgar score at 1 and 5 min will be recorded after delivery by the attending pediatric physician.

Hemodynamic changes mentioned above and the number of interventions including administration of ephedrine or atropine, stopping or re-starting of NE infusion, which will be applied by the physician to overcome the hemodynamic consequences of spinal anesthesia will all be recorded until the patient leaves the operating room.

Typ studie

Intervenční

Zápis (Odhadovaný)

80

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Abbasia
      • Cairo, Abbasia, Egypt, 00202
        • Ain Shams

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • A normal singleton pregnancy with a gestational age of ≥ 37 weeks. 18-40 years old pregnant women scheduled for elective C/S under spinal anesthesia.

Exclusion Criteria:

  • Any absolute contraindication to spinal block, Neurological or cardiac disorder, Basal systolic blood pressure above 140 mmHg or below 100 mmHg, Peripartum bleeding or emergent situations both for fetus and mother, Those who refused to participate in the study were excluded Known fetal abnormality, intrauterine growth restriction, Obstetric complication (ruptured membranes, placenta previa, placental abruption),

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Komparátor placeba: Non_obese + NE 0 mic/kg/min
Non_obese Patients BMI <30 kg/m2 receiving placebo (normal saline )infusion after spinal anesthesia.
normal saline infusion post spinal anesthesia .
Aktivní komparátor: Non_obese + NE 0.025mic/kg/min
Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.025mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Aktivní komparátor: Non_obese + NE 0.05mic/kg/min
Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.05mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Aktivní komparátor: Non_obese + NE 0.075mic/kg/min
Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.075mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Aktivní komparátor: Non_obese + NE 0.1mic/kg/min
Non_obese Patients BMI <30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.1mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Komparátor placeba: Obese + NE 0 mic/kg/min
Obese Patients BMI >30 kg/m2 receiving placebo (normal saline )infusion after spinal anesthesia.
normal saline infusion post spinal anesthesia .
Aktivní komparátor: Obese + NE 0.025 mic/kg/min
Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.025 mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Aktivní komparátor: Obese + NE 0.05 mic/kg/min
Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.05 mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Aktivní komparátor: Obese + NE 0.075 mic/kg/min
Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.075 mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .
Aktivní komparátor: Obese + NE 0.1 mic/kg/min
Obese Patients BMI>30 kg/m2 receiving prophylactic nor epinephrine infusion at 0.1 mic/kg/min after spinal anesthesia.
norepinephrine infusion doses ( 0.025, 0.05, and 0.075, 0.1 mic/kg/min) post spinal anesthesia .

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence of hypotension after spinal anesthesia
Časové okno: From spinal anesthesia until delivery of the fetus.
Hypotension defined as a ≥20% decrease in systolic blood pressure from baseline.
From spinal anesthesia until delivery of the fetus.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Reactive hypertension
Časové okno: From spinal anesthesia until the end of surgery.
Incidence of systolic blood pressure ≥20% above baseline.
From spinal anesthesia until the end of surgery.
Bradycardia
Časové okno: From spinal anesthesia until the end of surgery.
Heart rate <60 beats/min.
From spinal anesthesia until the end of surgery.
Nausea and vomiting
Časové okno: From spinal anesthesia until the end of surgery.
Incidence of maternal nausea and/or vomiting.
From spinal anesthesia until the end of surgery.
Apgar score at 1 minute
Časové okno: 1 minute after delivery.
Neonatal Apgar score.
1 minute after delivery.
Apgar score at 5 minutes
Časové okno: 5 minutes after delivery.
Neonatal Apgar score.
5 minutes after delivery.
Number of rescue interventions
Časové okno: From spinal anesthesia until the patient leaves the operating room.
Number of ephedrine doses, atropine doses, and norepinephrine infusion interruptions/restarts.
From spinal anesthesia until the patient leaves the operating room.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

9. července 2026

Primární dokončení (Odhadovaný)

20. ledna 2027

Dokončení studie (Odhadovaný)

20. dubna 2027

Termíny zápisu do studia

První předloženo

11. července 2026

První předloženo, které splnilo kritéria kontroly kvality

11. července 2026

První zveřejněno (Aktuální)

15. července 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

15. července 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

11. července 2026

Naposledy ověřeno

1. července 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • FMASU MD 46/2026

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .